CurrentBlue Cross Blue Shield - IowaPolicy 05.05.12

Panhematin (hemin) for acute hepatic porphyria — Coverage Criteria

Covers medical necessity criteria, documentation, dosing, and billing for Panhematin (hemin) treatment of acute hepatic porphyria for Wellmark Blue Cross and Blue Shield members; applies to prescribers and reviewers determining coverage under member contracts.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyPanhematin (hemin) for acute hepatic porphyria — Coverage Criteria

Policy CodePolicy 05.05.12

Change TypeNo material changes

Effective DateJan 1, 2024

Next Review DateOct 1, 2025

Key ActionObtain prior authorization with clinical documentation and ensure prescriber is experienced in porphyria management or in consultation with such a physician.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥16min age

6 moinitial approval

12 morenewal approval

≤6 mg/kg/daydose limit

J1640billing code

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Panhematin (hemin)

Initial approval (Acute Hepatic Porphyria)

Panhematin may be considered medically necessary when ALL of the following are met:

Initial approval criteria: 1. Member is 16 years of age or older. 2. Documented diagnosis of acute hepatic porphyria (AHP) with one of the following subtypes: Acute Intermittent Porphyria (AIP), Aminolevulinic Acid Dehydratase Deficiency Porphyria (ADP), Hereditary Coproporphyria (HCP), or Variegate Porphyria (VP). 3. Presence of clinical symptoms suggestive of an AHP attack (e.g., severe acute abdominal pain, nausea, vomiting, constipation, muscle weakness, neuropathy, tachycardia, hypertension, seizures, hyponatremia). 4. Laboratory confirmation of elevated porphobilinogen (PBG) in urine or plasma, or an elevated porphyrin level (plasma or fecal).

Approval will be for 6 months.

Continuation approval (Acute Hepatic Porphyria)

Panhematin may be considered medically necessary for continued treatment when ALL of the following are met:

Continuation criteria: 1. Member meets Criteria for Initial Approval. 2. Demonstrated positive clinical response while on Panhematin therapy compared to pre-treatment baseline, shown by improvement in signs and symptoms of AHP (e.g., severe acute abdominal pain, nausea, vomiting, constipation, muscle weakness, neuropathy, tachycardia, hypertension, seizures, hyponatremia). 3. No serious adverse effects with prior Panhematin therapy (e.g., anaphylactic reactions, renal or hepatic toxicity).

Approval will be for 12 months.

Panhematin (hemin) is not medically necessary when the member does not meet all required criteria for treatment of acute hepatic porphyria. Coverage requires documentation that the patient meets the specified initial or continuation approval conditions; requests that lack evidence of meeting those conditions may be denied.

Specifically, use of Panhematin is not medically necessary if the member fails to meet any one of the following: age ≥16 years; a documented diagnosis of an AHP subtype (Acute Intermittent Porphyria, Aminolevulinic Acid Dehydratase Deficiency Porphyria, Hereditary Coproporphyria, or Variegate Porphyria); presence of clinical symptoms consistent with an AHP attack (for example, severe acute abdominal pain, nausea, vomiting, constipation, muscle weakness, neuropathy, tachycardia, hypertension, seizures, or hyponatremia); or laboratory confirmation of elevated porphobilinogen in urine or plasma or elevated porphyrin levels (plasma or fecal).

Coding and Dosing Limits

Covered HCPCS CodesHCPCSCovered

J1640

Injection, hemin, 1 mg

Maximum hemin dosing per 24 hours

Maximum dose limitNot to exceed 6 mg/kg in any 24-hour period.

Typical dosing rangeStandard clinical practice: 3 to 4 mg/kg/day (given 1–4 mg/kg/day for 3–14 days based on clinical signs).

Dosing frequencyIn more severe cases, dose may be repeated no earlier than every 12 hours.

Provider Requirements, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required. Panhematin requests lacking required documentation (see below) or prescriber specialty information may be delayed or denied.

Prescriber must be a physician experienced in porphyria management (e.g., gastroenterologist, hematologist, hepatologist, neurologist) or consult with one.
Requests without documentation of age ≥ 16, documented AHP subtype, clinical symptoms of an AHP attack, or laboratory confirmation (elevated urine/plasma PBG or elevated plasma/fecal porphyrins) are at high risk for denial.

Note

Carbohydrate Loading Prior to Therapy

Before administering Panhematin, consider carbohydrate loading to reduce risk of exacerbating an attack; this is recommended practice prior to therapy.

Consider ~400 g glucose per day for 1–2 days prior to Panhematin administration.

Background

Acute hepatic porphyrias (AHP) are a group of inherited disorders that produce episodic neurovisceral attacks. Clinical features commonly include severe acute abdominal pain and a range of neurologic and autonomic manifestations such as nausea, vomiting, constipation, muscle weakness, neuropathy, tachycardia, hypertension, seizures, and hyponatremia. Hemin (Panhematin) is used to treat acute attacks when indicated by the clinical presentation and laboratory confirmation.

Definitions

Acute Hepatic Porphyria (AHP)

DefinitionAcute Hepatic Porphyria (AHP) is a group of inherited disorders that includes Acute Intermittent Porphyria (AIP), Aminolevulinic Acid Dehydratase Deficiency Porphyria (ADP), Hereditary Coproporphyria (HCP), and Variegate Porphyria (VP).

Diagnostic requirementsDiagnosis requires clinical symptoms suggestive of an AHP attack and laboratory confirmation of elevated porphobilinogen (urine or plasma) or elevated porphyrin level (plasma or fecal).

Typical clinical featuresSymptoms may include severe acute abdominal pain, nausea, vomiting, constipation, muscle weakness, neuropathy, tachycardia, hypertension, seizures, and hyponatremia.

FDA-approved indication notePanhematin is indicated for amelioration of recurrent attacks of acute intermittent porphyria when carbohydrate therapy is inadequate (see labeling).